You are here:

Pegylated liposomal doxorubicin (Caelyx®)

Advice

Following a full submission.

Not recommended for use within NHS Scotland.

This pegylated liposomal formulation of doxorubicin hydrochloride is now licensed as monotherapy for the treatment of metastatic breast cancer where there is an increased cardiac risk. An inconclusive study has suggested that it was not inferior to conventional doxorubicin in terms of progression-free survival. It was less cardiotoxic than conventional doxorubicin, but was associated with other troublesome adverse events, particularly palmarplantar erythrodysesthesia. The product is significantly more expensive than the standard preparation and its cost-effectiveness in managing metastatic breast cancer has not been addressed by the company in their submission.

Drug Details

Drug Name: Pegylated liposomal doxorubicin (Caelyx®)
SMC Drug ID: 84/03
Manufacturer: Schering-Plough Ltd
Indication: Metastatic breast cancer
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 12 January 2004

Back